AGENDA AT A GLANCE
8:50
IMAPAC’s Opening Address
Leadership Panel Discussion
Building Global Vaccine Partnerships
9:00
Leadership Panel Discussion: Forging Global Vaccine Partnerships
- Transitioning from emergency-driven collaborations to sustained vaccine partnerships for both pandemics and endemic diseases.
- Leveraging cross-sector partnerships to create a resilient vaccine ecosystem that addresses long-term global health challenges.
- Building trust and transparency between governments, international organizations, and the private sector for lasting collaboration.
- Capitalizing on mRNA breakthroughs to establish a global vaccine network capable of addressing future health threats.
- Innovating data-sharing, regulatory harmonization, and global governance for a unified global health response.
Moderator:
Panelists:
9:50
Driving Vaccine Adjuvants and Delivery Systems Development to Ensure Resilient and Scalable Supply
- The scientific considerations of tailoring vaccine adjuvants for modern vaccines.
- How to secure global supply of critical vaccine adjuvants and excipients.
- How Croda’s adjuvant systems portfolio and supply strategy can address the industry’s challenges.
- The scientific considerations of tailoring vaccine adjuvants for modern vaccines.
- How to secure global supply of critical vaccine adjuvants and excipients.
- How Croda’s adjuvant systems portfolio and supply strategy can address the industry’s challenges.
10:05
From Early-Stage Lab-Scale Process Development to Pilot and Commercial Scales: A Data-Driven Optimization Approach for a Multivalent Conjugate Vaccine Development and Its Commercialization
- Conjugate vaccine development is inherently complex. As a global leader, the Serum Institute of India applies advanced data analytics and Quality by Design (QbD) principles to optimize biologics research, development, and manufacturing. By integrating tools such as the Umetrics® Suite, we have significantly improved yield consistency and process robustness.
- This presentation will examine how advanced analytics and smart manufacturing are transforming vaccine production, including addressing complex scientific challenges, scaling early-stage data for commercial manufacturing, and leveraging real-time analytics through high-performance online sensors.
- It will also share insights into the use of data analytics platforms and QbD frameworks, highlighting how data-driven decision-making is driving meaningful advances in vaccine manufacturing.
10:30
Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Next-Gen Vaccines for Developing Nations
Tailoring Vaccine Development
11:10
Tailoring Vaccine Development for Feasible Economics, Efficient Deployment and Targeted Impact
- Platform technologies enable cost-efficient manufacturing, thermostability, simplified dosing, and flexible scale-up, aligning products with health system capacity and delivery channels.
- Targeting vaccine profiles to populations, geographies, and transmission dynamics enhances coverage, uptake, and real-world effectiveness.
- Integrating demand forecasting, market shaping, and policy with clinical development, tailored strategies can reduce costs, accelerate equitable access, and improve programmatic fit.
11:35
Cellulose-Based Chromatography Media for Virus Purification - Toward Safe and Efficient Vaccine Production
- For fast and simple viral vaccine production: cell surface‑mimetic chromatography media, Cellufine Sulphate.
- Case studies of virus purification using Cellufine Sulphate.
- For a more efficient process: innovative permeable cellulose beads, Cellufine MLP.
12:30
Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Development of Vaccines for Emerging Diseases
Accelerating Vaccine Research for New Threats
2:00
Role of Vaccine Impact Modelling in Translating Evidence into Policy
- Modelling has played an increasingly important role in informing decisions around immunization strategy, policy, and programs.
- Models have been used to integrate data and evidence from different domains to estimate, project, or forecast health and economic outcomes of vaccination.
- These models are applied under a variety of scenarios and assumptions to respond to pertinent questions.
2:25
Accelerating Vaccine Development for Emerging Diseases in Low-Resource Settings
- Innovative manufacturing and clinical approaches that shorten development timelines.
- Novel technologies that decrease manufacturing and delivery costs.
- Clinical studies that improve the integration of vaccines into national immunization schedules.
Essential Vaccines for Future Resilience
Long-term Health Security & Supportive Policies
2:50
Vaccination Strategies for Fragile, Conflict and Emergencies Settings
- In emergency settings, population displacement, overcrowding, poor sanitation, and malnutrition increase the risk of vaccine-preventable diseases like measles, polio, diphtheria, and yellow fever.
- Key challenges include limited access, broken cold-chain systems, shortage of health workers, high population mobility, and weak disease surveillance.
- Vaccine delivery strategies in fragile and emergency settings need to be distinct from routine immunization approaches, leveraging approaches like mobile teams and pre-positioned supplies
- Strategies include rapid vaccination campaigns, better coordination & communication initiatives, which can reduce infectious disease deaths by up to 60% in emergency settings.
3:15
Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Essential Vaccines for Future Resilience
Long-term Health Security & Supportive Policies
Happening in Regency Ballroom I
4:00
Novel Recombinant Vaccines to Combat Respiratory Infections
- At Mynvax, we work on development of novel recombinant protein sub-unit vaccines to combat respiratory infections.
- Our leading programs are in Influenza and RSV areas.
- We employ protein engineering-based techniques to develop novel candidates.
4:25
Reaching Zero Dose Children – Learnings from the Field
- Immunization Agenda 2030 (IA2030): A global strategy with the goal of reducing the number of zero-dose children by 50% by 2030 from the 2019 baseline.
- Gavi: Zero-Dose Immunization Program (ZIP) and the Equity Accelerator Fund, partnering with governments and NGOs to implement tailored, context-specific interventions.
- India's Efforts: India has made significant progress, reducing its share of global zero-dose children and implementing targeted programs
Manufacturing Analytics & Quality Assurance
4:50
The Role of Digital Systems in Enhancing Quality Oversight and Traceability
- Digital Transformation in Pharma. How automation, real-time monitoring, and integrated systems improve quality oversight and traceability.
- Key Technologies & Regulatory Alignment. AI-driven analytics, end‑to‑end digital workflows (ELN/LIMS), connecting experimental data and process control (SIMCA/JMP/MODDE; bioreactor SCADA) with ERP (SAP) for real‑time insights and audit readiness.
- Strategic Benefits & Industry Impact. Enhanced lifecycle traceability. Encryption, backup/restore, and standardized metadata enabling secure, compliant collaboration across R&D and manufacturing sites, improved compliance, and future trends shaping pharmaceutical excellence.
5:15
Chairman Closing Remarks
5:20
End of Conference - Day 1 | Cocktails & Networking
6:00
8:50
IMAPAC’s Opening Address
Breakthroughs in Vaccine Technologies
9:25
Innovative Adjuvants for Accessible Global Health
- INI-2002, a stable, scalable synthetic TLR4 agonist enabling high-performance adjuvant design.
- Adjuvant systems T4Q, T4SE, and T4AH combining INI-2002 with QS-21 GH/Infinity, matching top commercial systems at lower cost.
- Expanding access to advanced, affordable, and globally licensable adjuvant technologies.
9:40
Agentic AI-enabled Industrialized Animal-free Testing Strategy for Biopharmaceutical Workflows
- Introduction of the Digital Animal Replacement Technology (DART) platform, highlighting how it utilizes advanced, human-relevant in vitro micro physiological models integrated with AI & ML analytics to reduce reliance on animal testing.
Case Studies:
- Functional assessment of recombinant vaccine candidates.
- Screening vaccine formulations – a multiparametric approach to select the candidate through immunogenicity assessments – pipeline strengthening.
- Testing vaccine human neurovirulence risks as an in-house assessment parameter – democratizing the bioassay as an affordable strategy.
- Testing vaccine batches for release routed through an automated workflow integrated within a single web-based framework.
10:05
Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee
Scaling Up Vaccine Manufacturing
New-Age Automations & Advanced Technologies
11:00
Lessons from the Field: State of Vaccine Manufacturing in Africa
- Early African Vaccine Manufacturing targets, notably by Africa CDC, lacked clarity on ecosystem objectives and quantification.
- The Target Pathway provided a framework to map the manufacturing footprint to three objectives: pandemic preparedness, global market health, and commercial viability.
- To commercialize vaccines made in Africa, focus should be on reducing demand and allocation uncertainty, shortening regulatory and market entry timelines, and rebalancing funding between near-to-market vaccines and new projects.
11:50
Supplier Qualification: A cGMP Building Block for Sustainable Quality in Vaccine Manufacturing
- Role of supplier qualification in vaccine cGMP compliance – why supplier selection and control are critical to product quality, patient safety, and regulatory readiness in vaccine manufacturing.
- • Risk-based supplier onboarding process – key steps including supplier evaluation, audits, quality agreements, documentation review, and approval aligned with cGMP expectations.
- • Maintaining sustainable quality through supplier lifecycle management – ongoing monitoring, performance metrics, change control, and re-qualification to ensure long-term reliability and compliance.
12:15
Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Regulatory, Scientific, and Commercial Frameworks Shaping Vaccines and Biologics
Happening in Regency Ballroom I
2:25
Recent Developments in Pharmaceutical Regulations & Life Cycle Management
- Addressing the latest regulatory updates and their implications for effective product life cycle management.
- Best practices in sustaining compliance, addressing patient needs, and ensuring competitive positioning within the market.
3:15
Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Closing Panel: Forging India's Vaccine & Biologics Future
4:00
Plenary Discussion: What’s Next for Novel Vaccines & Biologics – Can Innovation, Strategy, and Collaboration Lead the Way?
- Shaping India and the Global South as leaders, not just manufacturers, in vaccines and biologics.
- Harnessing innovation and technology to deliver scalable, accessible solutions for developing nations.
- Building fair, accountable global partnerships that accelerate R&D and impact.
- Aligning policy and regulation to drive speed, quality, and trust.
- Preparing for future health challenges through strategic planning and innovation.
Moderator:
Panelists:
4:50
Chairman Closing Remarks
5:00
End of Conference
For Speaking Opportunities, Kindly Contact:
